Are RSV Shots for Babies Creating Dangerous Drug-Resistant Strains?: It was supposed to be a breakthrough in protecting infants. The monoclonal antibody nirsevimab—marketed as Beyfortus by Sanofi and AstraZeneca—was hailed as a game-changer in preventing RSV, a virus that fills children’s hospitals every winter. But now, a French study is raising alarms that could leave parents deeply unsettled: the very shot meant to shield babies may be spawning drug-resistant strains of RSV.
Are RSV Shots for Babies Creating Dangerous Drug-Resistant Strains?: It was supposed to be a breakthrough in protecting infants. The monoclonal antibody nirsevimab—marketed as Beyfortus by Sanofi and AstraZeneca—was hailed as a game-changer in preventing RSV, a virus that fills children’s hospitals every winter. But now, a French study is raising alarms that could leave parents deeply unsettled: the very shot meant to shield babies may be spawning drug-resistant strains of RSV.
Comments
Post a Comment